NCT04761861

Vildagliptin for Treatment of Antipsychotic-induced Dyslipidemia

Vildagliptin for Treatment of Antipsychotic-induced Dyslipidemia: a Randomized, Double-blind, Placebo-controlled Study

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Sadat City University · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

Almost all antipsychotics can induce dyslipidemia, but no treatment has been established. Vildagliptin can improve lipid levels in obese patients. The investigators conducted a randomized, placebo-controlled study to test the efficacy of vildagliptin for antipsychotic-induced dyslipidemia.

Conditions

• Schizophrenia
• Dyslipidemias

Interventions

Type	Name	Description
DRUG	Vildagliptin 50 MG	Vildagliptin 50 MG tablet once daily
DRUG	Placebo	Placebo one tablet daily

Timeline

• Start date: 2021-02-16
• Primary completion: 2025-12-31
• Completion: 2025-12-31
• First posted: 2021-02-21
• Last updated: 2025-07-14

Locations

1 site across 1 country: Egypt